Protocol Ledger

NCT07284849 · Phase III · RECRUITING

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Interventional Phase III clinical trial protocol NCT07284849 sponsored by Incyte in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-05 Enrollment: 700 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07284849
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)700 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07284849
Protocol FieldVerified Registry Value
NCT IdentifierNCT07284849
Consolidated Lead SponsorIncyte
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment700 participants (ESTIMATED)
Registered Start Date2026-03-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07284849
Hospital Research SiteLocationSite Profile
Providence Medical FoundationFullerton, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->
Hartford HospitalHartford, CTOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Incyte across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI